Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D and Wells PS, for the AVERT Investigators
N Engl J Med 2019; 380:711-719
CARDIONCOLOGY.ORG ABSTRACT:
This article reports the results from a randomized, placebo-controlled, double-blind clinical trial to assess the efficacy and safety of apixaban thromboprophylaxis in 574 ambulatory patients with cancer who were at intermediate-to-high risk for venous thromboembolism (VTE) and were initiating chemotherapy.
Results indicate that apixaban therapy led to a significantly lower rate of VTE compared to placebo. However, the rate of major bleeding episodes was higher with apixaban than with placebo.
© All rights reserved
Image source: https://www.nejm.org/doi/full/10.1056/NEJMoa1814468